Clinical Trial Update: Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed plus gemcitabine as first-line chemotherapy for malignant pleural or peritoneal mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peritoneal Mesothelioma
• Malignant Pleural Mesothelioma

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED